Up­dat­ed: Bridge­Bio's $2.4B part­ner­ship takes a sud­den hit as Helsinn plans to with­draw NDA on FGFR2 drug

Not two years af­ter the fam­i­ly-owned Swiss phar­ma Helsinn en­gi­neered a $2.4 bil­lion deal to get a piece of Bridge­Bio’s in­fi­gra­tinib — lat­er ap­proved as Trusel­tiq — it’s all com­ing to an abrupt end.

Lian­Bio, the biotech play­er that holds the Chi­na li­cense to the drug, flagged the news in an SEC dis­clo­sure — al­though it ap­pears that Bridge­Bio has pre­vi­ous­ly re­port­ed it in a Sep­tem­ber fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER